GRAND PHARMA Obtains Exclusive Rights to Market Allergy Medication Neffy in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: aastocks
Product Cooperation Agreement: GRAND PHARMA has entered into a product cooperation agreement with Pediatrix Therapeutics for the adrenaline nasal spray, Neffy.
Commercialization Rights: The Group will acquire exclusive commercialization rights in Mainland China and non-exclusive rights in Hong Kong for Neffy.
Localized Production Plans: GRAND PHARMA plans to achieve localized production of Neffy within 24 months after receiving product approval.
Short Selling Information: The company has reported short selling of $3.75 million with a ratio of 26.016%.
Analyst Views on 00512
Wall Street analysts forecast 00512 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00512 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 7.900
Low
Averages
High
Current: 7.900
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
